A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT ID: NCT06533059
Last Updated: 2025-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
110 participants
INTERVENTIONAL
2024-08-22
2027-12-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569
Study of AS1411 in Advanced Solid Tumours
NCT00881244
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104
NCT04349969
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
NCT00475956
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
NCT02517398
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ALTA2618
ALTA2618 will be administered continuously at a protocol-defined dose based on cohort assignment
ALTA2618
Oral ALTA2618 tablets will be administered at protocol-defined dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALTA2618
Oral ALTA2618 tablets will be administered at protocol-defined dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Unresectable or metastatic disease
* Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage
* Evaluable or measurable disease per RECIST v1.1
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate organ function.
Exclusion Criteria
* Patients known to have KRAS, NRAS, HRAS, or BRAF genomic alterations in their tumor
* Known condition that prohibits ability to swallow or absorb an oral medication
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alterome Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Medical Director
Role: STUDY_DIRECTOR
Alterome Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
La Jolla, California, United States
Research Site
Los Angeles, California, United States
Research Site
Denver, Colorado, United States
Research Site
Sarasota, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Boston, Massachusetts, United States
Research Site
Boston, Massachusetts, United States
Research Site
St Louis, Missouri, United States
Research Site
Mineola, New York, United States
Research Site
New York, New York, United States
Research Site
Maumee, Ohio, United States
Research Site
Nashville, Tennessee, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site #2
San Antonio, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Fairfax, Virginia, United States
Research Site
Madison, Wisconsin, United States
Research Site
Blacktown, New South Wales, Australia
Research Site
Randwick, New South Wales, Australia
Research Site
South Brisbane, Queensland, Australia
Research Site
Malvern, Victoria, Australia
Research Site
Nedlands, Western Australia, Australia
Research Site
Caen, , France
Research Site
Dijon, , France
Research Site
Saint-Herblain, , France
Research Site
Villejuif, , France
Research Site
Kyoto, , Japan
Research Site
Matsuyama, , Japan
Research Site
Shizuoka, , Japan
Research Site
Tokyo, , Japan
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Barcelona, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Valencia, , Spain
Research Site
Changhua, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Newcastle upon Tyne, , United Kingdom
Research Site
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2618-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.